Cargando…

Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses

Detalles Bibliográficos
Autores principales:	Molenaar, Remco J., Maciejewski, Jaroslaw P., Wilmink, Johanna W., van Noorden, Cornelis J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887841/ https://www.ncbi.nlm.nih.gov/pubmed/30140044 http://dx.doi.org/10.1038/s41388-018-0455-1

Ejemplares similares

Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy
por: Molenaar, Remco J., et al.
Publicado: (2021)

In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma
por: Khurshed, Mohammed, et al.
Publicado: (2017)

Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in IDH1-Mutated Cancer Cells
por: Khurshed, Mohammed, et al.
Publicado: (2022)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors
por: Khurshed, Mohammed, et al.
Publicado: (2021)

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours
por: Molenaar, Remco J, et al.
Publicado: (2017)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
por: Bergaggio, Elisa, et al.
Publicado: (2019)

The NADP(+)-dependent IDH1 mutation and its relevance for glioblastoma patient survival
por: Van Noorden, Cornelis JF
Publicado: (2014)

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
por: Molenaar, Remco J., et al.
Publicado: (2018)

CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma?
por: Hira, Vashendriya V.V., et al.
Publicado: (2020)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

Correction to: Cancer-Related Fatigue: Causes and Current Treatment Options
por: Thong, Melissa S.Y., et al.
Publicado: (2022)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
por: Rimini, Margherita, et al.
Publicado: (2022)

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
por: Zarei, Mehrdad, et al.
Publicado: (2022)

Correction: A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1
por: Klink, Barbara, et al.
Publicado: (2013)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Enzyme Redesign Guided by Cancer-Derived IDH1 Mutations
por: Reitman, Zachary J., et al.
Publicado: (2012)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Correction: Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

Molecular landscape of IDH ‐wild type, pTERT ‐wild type adult glioblastomas
por: Liu, Emma Munan, et al.
Publicado: (2022)

Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions
por: Nijland, Philip G., et al.
Publicado: (2015)

Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab
por: Hwang, Helen, et al.
Publicado: (2022)

Correction: Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma
por: Verbovšek, Urška, et al.
Publicado: (2015)

Mutations and Copy Number Alterations in IDH Wild-Type Glioblastomas Are Shaped by Different Oncogenic Mechanisms
por: Ülgen, Ege, et al.
Publicado: (2020)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer
por: Zarei, Mehrdad, et al.
Publicado: (2023)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Analyses of metastasis-associated genes in IDH wild-type glioma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
por: Bassal, Mahmoud A., et al.
Publicado: (2022)

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
por: Kikuchi, Zensho, et al.
Publicado: (2020)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r0cpkiqkl3ae6vro7rkoj63ncu